Table 2. Correlation between preoperative serum tumor makers and major clinicopathological traits in the training cohort.
| Patient characteristics | Cases n (%) | CA125 (+)n (%) | P | CA19-9 (+)n (%) | P | CEA (+)n (%) | P | ||
|---|---|---|---|---|---|---|---|---|---|
| Gender | Male | 702 (68.6) | 272 (38.7) | 0.001 | 125 (17.8) | 0.009 | 148 (21.1) | 0.027 | |
| Female | 322 (31.4) | 161 (50.0) | 80 (24.8) | 49 (15.2) | |||||
| Age (ys) | <60 | 564 (55.1) | 233 (41.3) | 0.485 | 100 (17.7) | 0.043 | 99 (17.6) | 0.130 | |
| ≥60 | 460 (44.9) | 200 (43.5) | 105 (22.8) | 98 (21.3) | |||||
| Tumor location | Upper | 252 (24.6) | 93 (36.9) | 0.029 | 50 (19.8) | 0.012 | 61 (24.2) | 0.146 | |
| Middle | 223 (21.8) | 110 (49.3) | 56 (25.1) | 40 (17.9) | |||||
| Lower | 529 (51.7) | 219 (41.4) | 91 (17.2) | 92 (17.4) | |||||
| Whole | 20 (2.0) | 11 (55.0) | 8 (40.0) | 4 (20.0) | |||||
| Tumor size (cm) | ≤2 | 140 (13.7) | 49 (35.0) | <0.001 | 14 (10.0) | <0.001 | 13 (9.3) | <0.001 | |
| 2-5 | 487 (47.6) | 180 (37.0) | 90 (18.5) | 83 (17.0) | |||||
| 5-8 | 308 (30.1) | 162 (52.6) | 76 (24.7) | 78 (25.3) | |||||
| >8 | 89 (8.7) | 42 (47.2) | 25 (28.1) | 23 (25.8) | |||||
| Macroscopic type | Type-0 | 161 (15.7) | 53 (32.9) | 0.002 | 19 (11.8) | 0.001 | 15 (9.3) | 0.012 | |
| Type-1 | 38 (3.7) | 14 (36.8) | 7 (18.4) | 9 (23.7) | |||||
| Type-2 | 443 (43.3) | 185 (41.8) | 87 (19.6) | 90 (20.3) | |||||
| Type-3 | 333 (32.5) | 159 (47.7) | 76 (22.8) | 73 (21.9) | |||||
| Type-4 | 49 (4.8) | 22 (44.9) | 16 (32.7) | 10 (20.4) | |||||
| Differentiation grade | Well | 17 (1.7) | 3 (17.6) | 0.016 | 0 (0.0) | 0.064 | 2 (11.8) | 0.413 | |
| Moderate | 193 (18.8) | 71 (36.8) | 33 (17.1) | 43 (22.3) | |||||
| Poor | 814 (79.5) | 359 (44.1) | 172 (21.1) | 152 (18.7) | |||||
| pT stage | T1 | 188 (18.4) | 60 (31.9) | <0.001 | 19 (10.1) | <0.001 | 14 (7.4) | <0.001 | |
| T2 | 120 (11.7) | 40 (33.3) | 16 (12.3) | 19 (15.8) | |||||
| T3 | 106 (10.4) | 47 (44.3) | 13 (12.3) | 15 (14.2) | |||||
| T4 | 610 (59.6) | 286 (46.9) | 157 (25.7) | 149 (24.4) | |||||
| pN stage | N0 | 310 (30.3) | 109 (35.2) | <0.001 | 31 (10.0) | <0.001 | 31 (10.0) | <0.001 | |
| N1 | 199 (19.4) | 73 (36.7) | 39 (19.6) | 33 (16.6) | |||||
| N2 | 191 (18.7) | 78 (40.8) | 39 (20.4) | 42 (22.0) | |||||
| N3a | 216 (21.1) | 109 (50.5) | 55 (25.5) | 60 (27.8) | |||||
| N3b | 108 (10.5) | 64 (59.3) | 41 (38.0) | 31 (28.7) | |||||
| M stage | M0 | 937 (91.5) | 381 (40.7) | 0.001 | 173 (18.5) | <0.001 | 167 (17.8) | <0.001 | |
| M1 | 87 (8.5) | 52 (59.8) | 32 (36.8) | 30 (34.5) | |||||
| pTNM stage | I | 221 (21.6) | 69 (31.2) | <0.001 | 22 (10.0) | <0.001 | 19 (8.6) | <0.001 | |
| II | 201 (19.6) | 70 (34.8) | 24 (11.9) | 25 (12.4) | |||||
| III | 515 (50.3) | 242 (47.0) | 127 (24.7) | 123 (23.9) | |||||
| IV | 87 (8.5) | 52 (59.8) | 32 (36.8) | 30 (34.5) | |||||